A drug newly listed on the Pharmaceutical Benefits Scheme promises to improve the life expectancy of patients with type-2 diabetes. Clinical trials have shown encouraging results - reduced blood glucose levels and cardiovascular death in diabetic patients.
A drug newly listed on the Pharmaceutical Benefits Scheme promises to improve the life expectancy of patients with type-2 diabetes. Clinical trials have shown encouraging results - reduced blood glucose levels and cardiovascular death in diabetic patients.
